Nanovaccines of polydopamine@tumor-associated antigens with robust prophylactic and therapeutic efficacy for cancer immunotherapy

Key Points

• This research focuses on creating nanovaccines that target tumor-associated antigens to enhance immunotherapy against cancer.
• Developed nanovaccines using polydopamine and tumor-associated antigens.
• Evaluated prophylactic and therapeutic efficacy in preclinical cancer models.
• Conducted immune response assessments and efficacy measurements.
• Nanovaccines showed significant reduction in tumor growth.
• Enhanced immune responses were observed in treated models.
• Promising results indicate potential for clinical application in cancer therapy.